Laboratorios Leti, a CataloniaBio member, has signed an agreement with the multinational MSD Animal Health to distribute its canine leishmaniasis vaccine LetiFend® in France, Italy, Greece and the United Kingdom. Leti will continue to manage the Spanish and Portuguese markets directly.
LetiFend® is the first recombinant vaccine available in Europe to prevent canine leishmaniasis, a global zoonosis caused by Leishmania infantum, which is potentially deadly and prevalent in more than 80 countries around the world. Moreover, there are few treatment possibilities, which highlights the importance of vaccination to strengthen the immune system before infection.
According to Laboratorios Leti President Jaime Grego, "This deal is extremely important as it will allow us to increase the vaccination rate and help not only prevent canine leishmaniasis on a global level but also control the occurrence of this disease in humans.”
In August 2016, Leti was granted authorisation to market the vaccine by the European Commission.
Comments